InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（10 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
10
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the full record of transactions filed by Sethuraman Natarajan, President, Research & Develop.. Officer active across 1 company, notably Entrada Therapeutics, Inc.. Cumulatively, 21 reports have been recorded. Split: 0 buy · 10 sells. Total volume traded: €538k. History available since 1 March 2022. The latest transaction was disclosed on 2 September 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Sethuraman Natarajan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
2,079 股@ US$7.14390.0055% mcap2.3% 占其流量Common StockSEC:0001873394-26-000005:0
25,907 股@ US$15.39390.14% mcap50.0% 占其流量Common StockSEC:0001873394-26-000003:0
55,800 股0Common StockSEC:0001873394-26-000001:0
1,760 股@ US$5.43021.5% 占其流量Common StockSEC:0001873394-25-000003:0
60,800 股0Common StockSEC:0001689375-25-000012:0
100 股@ US$20.000.2% 占其流量Common StockSEC:0001689375-24-000067:0
1,409 股@ US$20.00793.0% 占其流量Common StockSEC:0001689375-24-000066:0
749 股@ US$18.0221.4% 占其流量Common StockSEC:0001689375-24-000064:0
600 股@ US$18.001.1% 占其流量Common StockSEC:0001689375-24-000057:0
600 股@ US$15.23560.9% 占其流量Common StockSEC:0001689375-24-000053:0
469 股@ US$15.76110.8% 占其流量Common StockSEC:0001689375-24-000050:0
600 股@ US$18.001.1% 占其流量Common StockSEC:0001689375-24-000041:0
1,000 股@ US$15.001.6% 占其流量Common StockSEC:0001689375-24-000031:0
44,100 股0Common StockSEC:0001689375-24-000003:0
14,200 股0Common StockSEC:0001689375-23-000063:0
3,026 股@ US$18.0025.6% 占其流量Common StockSEC:0001689375-23-000046:0
3,961 股@ US$18.00457.4% 占其流量Common StockSEC:0001689375-23-000031:0
14,200 股0Common StockSEC:0001689375-23-000029:0
28,400 股0Common StockSEC:0001689375-23-000014:0
5,794 股0Common StockSEC:0001104659-22-097876:0
11,588 股0Common StockSEC:0001104659-22-030008:0
21 条申报中的 21 条
About Sethuraman Natarajan
Sethuraman Natarajan is President, Research & Develop. at Entrada Therapeutics, Inc. (XNAS). He has 20 filings in total, and across the sampled recent filings from 2022-03-03 to 2026-05-04, sales total 538390 EUR and the modal transaction nature is Sell.
